A randomized, double-blind, parallel, single dose comparative pharmacokinetic study of AryoTrust (Trastuzumab) powder for concentrate for solution for intravenous infusion and 'HERCEPTIN' (Trastuzumab) powder for concentrate for solution for intravenous infusion in healthy, adult, male subjects
Latest Information Update: 01 Apr 2021
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Gastric cancer; Male breast cancer
- Focus Pharmacokinetics
- Sponsors AryoGen Pharmed
Most Recent Events
- 26 Sep 2019 New trial record